REGENXBIO, Inc. Forecast, price target & analysts
REGENXBIO, Inc. Target price 2025 - Analyst rating & recommendation
REGENXBIO, Inc. Classifications & Recommendation:
REGENXBIO, Inc. Price Target
| Target Price | $32.13 |
| Price | $9.12 |
| Potential |
252.30%
register free of charge
|
| Number of Estimates | 14 |
|
14 Analysts have issued a price target REGENXBIO, Inc. 2026 .
The average REGENXBIO, Inc. target price is $32.13.
This is
252.30%
register free of charge
$54.60
498.68%
register free of charge
$14.14
55.04%
register free of charge
|
|
| A rating was issued by 18 analysts: 16 Analysts recommend REGENXBIO, Inc. to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the REGENXBIO, Inc. stock has an average upside potential 2026 of
252.30%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 83.33 | 300.19 |
| 7.66% | 260.24% | |
| EBITDA Margin | -256.97% | 16.86% |
| 7.55% | 106.56% | |
| Net Margin | -272.53% | -28.68% |
| 6.66% | 89.48% |
14 Analysts have issued a sales forecast REGENXBIO, Inc. 2025 . The average REGENXBIO, Inc. sales estimate is
This results in the following potential growth metrics:
9 Analysts have issued an REGENXBIO, Inc. EBITDA forecast 2025. The average REGENXBIO, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
14 REGENXBIO, Inc. Analysts have issued a net profit forecast 2025. The average REGENXBIO, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -4.59 | -1.71 |
| 23.75% | 62.75% | |
| P/E | negative | |
| EV/Sales | 0.46 |
14 Analysts have issued a REGENXBIO, Inc. forecast for earnings per share. The average REGENXBIO, Inc. EPS is
This results in the following potential growth metrics and future valuations:
REGENXBIO, Inc....
Current REGENXBIO, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Aug 19 2025 |
| Barclays |
Locked
➜
Locked
|
Locked | Aug 08 2025 |
| Chardan Capital |
Locked
➜
Locked
|
Locked | Aug 08 2025 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Aug 08 2025 |
| Chardan Capital |
Locked
➜
Locked
|
Locked | Jun 09 2025 |
| Goldman Sachs |
Locked
➜
Locked
|
Locked | Apr 17 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 21 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Aug 19 2025 |
|
Locked
Barclays:
Locked
➜
Locked
|
Aug 08 2025 |
|
Locked
Chardan Capital:
Locked
➜
Locked
|
Aug 08 2025 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Aug 08 2025 |
|
Locked
Chardan Capital:
Locked
➜
Locked
|
Jun 09 2025 |
|
Locked
Goldman Sachs:
Locked
➜
Locked
|
Apr 17 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 21 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
